Cardiovascular Systems Inc Annual Meeting of Stockholders
November 16, 2016

Corporate Profile

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease.

The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.

The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital... More >>

Recent News

More >>
Cardiovascular Systems, Inc. Signs Distribution Agreement with Medikit Co., Ltd. for Japan 11/14/16
Medikit will be Exclusive Japanese Provider of CSI’s Diamondback 360 ® Atherectomy Systems; Agreement Includes $10 million Upfront Payment to CSI Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) has signed an exclusive distribution agreement with Medikit Co., Ltd. to sell its Diamondback 360® Coronary and Peripheral Orbital Atherectomy Systems (OAS) in Japan. Medikit is one of the world's leading manufacturers in vascular access and interventional medical devices, especially hemodialysis and other catheters used by hospitals for coronary and peripheral interventions. Medikit’s Japanese sales channel includes 120 sales representatives selling products to over 800 hospitals that perform percutaneous coronary interventions. To secure exclusive distribution rights, Medikit will make an upfront payment of $10 million to CSI. “The presence of severely calcified coronary lesions contributes to both poor patient outcomes and higher treatment costs,” said Nobufumi Kurita, President, Medikit...
More >>
Cardiovascular Systems, Inc. in Collaboration with Cardiovascular Research Foundation Debuts Largest Randomized Trial to Study Coronary Atherectomy for Calcified Coronary Lesions at Transcatheter Cardiovascular Therapeutics Conference 11/01/16
ECLIPSE trial compares treatment strategies for patients with calcified coronary arteries Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), today debuted the design of its new ECLIPSE clinical trial in a presentation at the Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, D.C. The trial will compare CSI’s Diamondback 360® Coronary Orbital Atherectomy System (OAS) versus conventional angioplasty, including specialty balloons, for vessel preparation prior to drug-eluting stent (DES) implantation. “The ECLIPSE trial reflects the growing complexity of coronary artery disease (CAD) seen in the modern-day cardiac catheterization laboratory, and will be the largest randomized clinical trial to date to assess the use of adjunctive coronary atherectomy for calcific coronary artery disease,” said Dr. Ajay Kirtane , director of the Cardiac Catheterization Laboratories at NewYork-Presbyterian/Columbia University Irving Medical Center , and co-principal investigator of...
More >>